De Lorijn, 2004 (median, 25 to 75th centiles) | 58 (37 to 92) | - | 10 (5 to 16) | - | 10 (5 to 18) | - | 32 (18 to 63) | - |
Benninga, 1995 (mean, range)
(mean and upper limit mean ± 2SD for healthy controls) | PCa: 79.3 (2.4 to 384)
Isolated ES: 41.4 (16.6 to 104.4) | RAPa: 32.5 (4.8 to 69.6)
Healthy controlsb: 29. 0 (62) | PC: 13.2 (<1.2 to 60)
Isolated ES: 7.9 (<1.2 to 26.4) | RAP: 7.7 (1.2 to 21.6)
Healthy controls: 7.7 (18) | PC: 16.1 (<1.2 to 11.4)
Isolated ES: 6.8 (<1.2 to 25.2) | RAP: 7.0 (1.2 to 25.2)
Healthy controls: 8.7 (20) | PC: 49.7 (<1.2 to 226.8)
Isolated ES: 26.7 (4.8 to 93.6) | RAP: 18.9 (1.2 to 49.2)
Healthy controls: 12. (34) |
Gutierrez, 2002 (mean ± SD, ranges) | 49.57 ± 25.38 (15.6 to 122.4) | 29.08 ± 8.30 (14.4 to 50) | 9.53 ± 9.07 (2.4 to 36) | 7.52 ± 5.75 (2.4 to 15.6) | 15.41 ± 13.13 (2.4 to 32) | 6.60 ± 6.20 (2.4 to 24) | 24.20 ± 16.77 (4.8 to 69.6) | 14.96 ± 8.70 (2.4 to 19.2) |
Papadopoulou, 1994 | No accurate figures reported | - | No accurate figures reported | - | No accurate figures reported | - | No accurate figures reported | - |
Corazziari, 1985 (mean ± SD, range) | No accurate figures reported | 25.0 ± 3.7 (19 to 33) | No accurate figures reported | No accurate figures reported | No accurate reported figures |
Benninga, 1996 (median, range) | PSTCc: 189 (104.4 to 380.4)
NDTCc: 46.8 (3.6 to 99.6) | - | PSTC: 27.0 (3.6 to 60)
NDTC: 8.4 (0 to 32.4) | - | PSTC: 37.2 (0 to 110.4)
NDTC: 7.2 (0 to 36.0) | - | PSTC: 116 (49.2 to 226.8)
NDTC: 27.0 (0 to 90.0) | - |
Yang, 2005 (mean ± SD) | 59.9 ± 2.3 | 14.8 ± 0.8 | 20.3 ± 1.2 | 7.3 ± 1.1 | 12.8 ± 1.7 | 3.4 ± 0.8 | 26.8 ± 1.4 | 4.1 ± 1.2 |
Cucchiara, 1984 (mean ± SD, range) | Patients with soiling: 58 ± 14.3 (36 to 86)
Patients without soiling: 61.1 ± 15 (36 to 96) | 25.6 ± 3.7 (19 to 33) | No accurate figures reported | No accurate figures reported | No accurate figures reported |
Martelli, 1998 (median, range)
(Controls' values taken from Arhan et al., 1983) | C+E patientsd: 67.2 (2 to 168)
C+4d patients: 54.6 (9 to 168)
C-4d patients: 49.6 (8 to 161) | 22.8 (9.4 to 56.4) | C+E patients: 14 (0 to 144)
C+4 patients: 12 (0 to 48)
C-4 patients: 14.8 (0 to 96) | 7.2 (0.6 to 19.2) | C+E patients: 13.6 (0 to 96)
C+4 patients: 12 (0 to 96)
C-4 patients: 12.4 (0 to 72) | 7.4 (1.2 to 22.8) | C+E patients: 30.2 (0 to 142)
C+4 patients: 26.4 (0 to 108)
C-4 patients: 18.4 (0 to 106) | 10.4 (1.21 to 34.2) |
Arhan, 1983 France (min; mean ± SD) | Not measured | 13:24 ± 1:5 | 7:10 ± 1:4 | 13:49 ± 1:37 | 7:37 ± 1:3 | 30:22 ± 2:42 | 11:4 ± 1:5 |
Staiano, 1993 Italy (mean ± SD) | 106.4 ± 6.1 | 98.6 ± 5.1 (FFR) | No accurate figures reported but N.S differences between 2 groups | 7.3 ± 1.3 | 3.0 ± 1.0 (FFR) | No accurate figures reported but N.S differences between 2 groups |
Zaslavsky, 2004 Brazil (mean ± SD, median and range) | 62.9 ± 12.6 69 (62.9 to 12.6) | 30.2 ± 13.2 27.5 (10.8 to 50.4)e | 18.6 ± 15 13.2 (12 to 54) | 6.7 ± 3.9 4.8 (1.2 to 12) | 24.3 ± 13.7 22.8 (2.4 to 51.6) | 7.9 ± 7.8 7.2 (0− 28.8) | 20 ± 15.7 18 (0 to 54) | 15.6 ± 10.7 12 (3.6 to 36) |
Koletzko, 1993 Switzerland (mean ± SD) | 70.0 ± 42.6 | - | Not reported, not clear whether measured | - | Not reported, not clear whether measured | - | Not reported, not clear whether measured | - |
Zaslavsky, 1998 Brazil (mean ± SD, median and range) | 58.25 ± 17.46 68.4 (27.6 to 72) | 30.18 ± 13.15 27.5 (10.8 to 50.4) | 15.97 ± 12.48 13.7 (2.4 to 43.2) | 6.74 ± 3.91 7.2 (1.2 to 12) | 24.74 ± 13.39 25.7 (7.2 to 51.6) | 7.94 ± 7.82 7.2 (0 to 28.8) | 17.60 ± 16.25 16.6 (0 to 49.2) | 15.58 ± 10.69 12 (3.6 to 36) |
Bijos, 2007 Poland (mean, estimates from a bar chart) | With faecal impaction on USf: 67
Without faecal impaction on US: 42 | - | With faecal impaction on US: 9
Without faecal impaction on US: 8 | - | With faecal impaction on US: 18
Without faecal impaction on US: 9 | - | With faecal impactio n on US: 32
Without faecal impactio n on US: 16 | - |
de Lorijn, 2005 The Netherlands (mean) | 92
(children with PC)g | 37
(children with FNRFIg and FAPg) | Not reported, not clear whether measured |
Cook, 2005 Australia | Values expressed as percentage of radioactivity at different times |
Vattimo, 1994 Italy (mean ± SD) | Normal transit: 27.79 ± 4.10
Mainly rectosigmoi d retention: 53.36 ± 29.66
Prolonged transit in all segments: 62.09 ± 7.23
More prolonged transit in rectosigmoid: 92.36 ± 24.16 | - | Normal transit: 9.11 ± 2.53
Mainly rectosigmo id retention: 10.38 ± 2.34
Prolonged transit in all segments: 21.81 ± 5.29
More prolonged transit in rectosigmoid: 19.78 ± 9.03 | - | Normal transit: 9.80 ± 3.50
Mainly rectosigmo id retention: 10.40 ± 4.00
Prolonged transit in all segments: 23.32 ± 6.14
More prolonged transit in rectosigmoid: 21.05 ± 5.70 | - | Normal transit: 8.88 ± 4.09
Mainly rectosigmoid retention: 32.58 ± 29.64
Prolonged transit in all segments: 16.95 ± 4.52
More prolonge d transit in rectosigm oid: 51.53 ± 17.82 | - |
Shin, 2002 Korea, Australia | Actual figures for CTT not reported |
Chitkara, 2004 USA | Values expressed as percentage of radioactivity at 24 h |